bearish

Biopharma Week in Review - September 30, 2024

60 Views01 Oct 2024 08:33
Issuer-paid
We review last week’s biopharma news for meaningful clinical data, regulatory updates, research innovation, and M&A. Last week, BMY received landmark antipsychotic approval
What is covered in the Full Insight:
  • Bristol-Myers Squibb Approval
  • Biohaven Phase 3 Success
  • Amgen's Clinical Data
  • AstraZeneca and Daiichi Sankyo Setback
  • Pfizer's Oxbryta Withdrawal
SUMMARY
(Sign Up to Access)
Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
  • Unlock research summaries
  • Follow top, independent analysts
  • Receive personalised alerts
  • Access Analytics, Events and more

Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.

Upgrade later to our paid plans for full-access.

or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 12-minute read)
Discussions
(Paid Plans Only)
chart-bar
Logo
Water Tower Research
Research from Water Tower Research
Water Tower Research
Equity Bottom-UpThematic (Sector/Industry)
  • Biopharma Week in Review - September 30, 2024
    01 Oct 2024
x